17,261 trials
Infectious Skin Diseases · Bacterial Skin Diseases · Staphylococcal Skin Infections
Primary: Number of Participants With a Clinical Response of Cure — 38; 34; 37 Participants
Uterine Cervical Neoplasms
Primary: Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population) — 8; 7; 11; 6 participant
Tuberculosis
Primary: Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC) — 0.98; 0.98; 0.96; 0.95 Percentage — p=<0.001
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax) — 54.83; 56.87; 1.92; -2.95 centimeters of water (cm H20) — p=0.068
Cardiovascular Disease · Hypertension · Hyperlipidemia
Primary: Systolic Blood Pressure — 121.7; 129.7 mm Hg
Breast Neoplasms · Breast Cancer
Primary: Number of Subjects With Response (Complete or Partial) — 0; 1; 20; 31 participants
Submassive Pulmonary Embolism
Primary: Number of Participants With Major Bleeding Events — 1; 0; 0; 0 participants
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
Urologic Neoplasms
Primary: Best Overall Tumor Response — 2; 13; 13; 1 participants
Mucopolysaccharidosis I · Hurler Syndrome · Hurler-Scheie Syndrome
Primary: Safety Evaluation — 16; 4; 5; 3 participants
Fabry Disease
Primary: Globotriaosylceramide (GL-3) Clearance in Capillary Endothelium in the Skin — 2; 14; 5; 0 patients
Behcet Syndrome · Behcet Disease · Mucocutaneous Ulceration
Primary: Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. — 13; 10; 12 patients with sustained response — p=0.404
Metastatic Colorectal Cancer
Primary: Best Overall Tumor Response — 6; 18; 15; 5 participants
Head and Neck Cancer
Primary: Response Rate — 2; 1 participants
Non-Small Cell Lung Cancer
Primary: The Feasibility of Post-Surgery Chemotherapy — 38; 27; 18; 6 participants